Combined pharmaceutical preparation for treatment of type 2 diabetes
AssigneeKissei Pharmaceutical Co., Ltd.
InventorsYuji Kiyono, Yoshio Okubo, Katsumi Hontani, Imao Mikoshiba, Kazuma Ojima
Life of this patent
Estimating the term…
Abstract
For controlling the condition of type 2 diabetes, a pharmaceutical including a combination of mitiglinide, a pharmacologically acceptable salt thereof or a hydrate thereof and an α-glucosidase inhibitor such as voglibose or acarbose, and a therapeutic method using the pharmaceutical are provided. The pharmaceutical according to the present invention has an extremely strong effect of decreasing a morning fasting blood glucose level, a postprandial blood glucose level and HbA1C of a patient with type 2 diabetes, and can improve glucose spike, insulin resistance and lipid metabolism.
Claims7
A method for decreasing a morning fasting blood glucose level, wherein a combined pharmaceutical consisting essentially of (1) mitiglinide calcium hydrate and (2) an α-glucosidase inhibitor is orally administered before every meal to a patient with type 2 diabetes having a hemoglobin A1C (HbA1C) value of at least 6.5% even with administration of the α-glucosidase inhibitor selected from voglibose and acarbose for improving a course of postprandial blood glucose, wherein a single dose of mitiglinide calcium hydrate is 5-45 mg.
A method for decreasing hemoglobin A1C (HbA1C), wherein a combined pharmaceutical consisting essentially of (1) mitiglinide calcium hydrate and (2) an α-glucosidase inhibitor is orally administered before every meal to a patient with type 2 diabetes having a hemoglobin A1C (HbA1C) value of at least 6.5% even with administration of the α-glucosidase inhibitor selected from voglibose and acarbose for improving a course of postprandial blood glucose, wherein a single dose of mitiglinide calcium hydrate is 5-45 mg.
A method for suppressing glucose spike which is an increase of blood glucose level occurring within 1 hour after a meal, wherein a combined pharmaceutical consisting essentially of (1) mitiglinide calcium hydrate and (2) an α-glucosidase inhibitor is orally administered before every meal to a patient with type 2 diabetes having a hemoglobin A1C (HbA1C value of at least 6.5% even with administration of the α-glucosidase inhibitor selected from voglibose and acarbose for improving a course of postprandial blood glucose, wherein a single dose of mitiglinide calcium hydrate is 5-45 mg.
Dependencies are inferred from the claim text.